rosiglitazone has been researched along with Cryptogenic Fibrosing Alveolitis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Caporarello, N; Choi, KM; Haak, AJ; Jones, DL; Ligresti, G; Manlove, LJ; Meridew, JA; Prakash, YS; Tan, Q; Tschumperlin, DJ | 1 |
1 other study(ies) available for rosiglitazone and Cryptogenic Fibrosing Alveolitis
Article | Year |
---|---|
PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state.
Topics: Actins; Animals; beta-Galactosidase; Bleomycin; Cell Line; Cellular Senescence; Collagen Type I; Collagen Type I, alpha 1 Chain; Cyclin-Dependent Kinase Inhibitor p16; Fibroblasts; Fibronectins; Gene Expression; Gene Knockdown Techniques; Humans; Hypoglycemic Agents; Idiopathic Pulmonary Fibrosis; Mice; Mitochondria; NAD; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Primary Cell Culture; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Triiodothyronine | 2019 |